Wellington Management Group LLP Sells 210,233 Shares of Insmed Incorporated (NASDAQ:INSM)

Wellington Management Group LLP reduced its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 21.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 752,226 shares of the biopharmaceutical company's stock after selling 210,233 shares during the period. Wellington Management Group LLP owned about 0.42% of Insmed worth $51,934,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Steward Partners Investment Advisory LLC lifted its position in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC grew its position in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 248 shares during the last quarter. Spire Wealth Management bought a new position in Insmed in the fourth quarter valued at about $47,000. Smartleaf Asset Management LLC boosted its stake in shares of Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Insmed during the fourth quarter valued at about $86,000.

Insmed Trading Down 8.2 %

Shares of INSM stock traded down $5.53 during trading hours on Thursday, reaching $62.02. The company's stock had a trading volume of 340,588 shares, compared to its average volume of 2,257,681. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91. The stock has a market capitalization of $11.23 billion, a P/E ratio of -11.18 and a beta of 1.07. The firm's fifty day simple moving average is $76.71 and its 200 day simple moving average is $73.73.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Equities research analysts expect that Insmed Incorporated will post -4.56 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on INSM shares. Wells Fargo & Company lifted their price objective on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. Royal Bank of Canada restated an "outperform" rating and issued a $100.00 price objective on shares of Insmed in a research note on Wednesday, March 19th. Stifel Nicolaus dropped their price target on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research report on Friday, February 21st. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Finally, Truist Financial upped their target price on Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $94.00.

Insider Transactions at Insmed

In related news, CFO Sara Bonstein sold 1,066 shares of the company's stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.72, for a total transaction of $67,925.52. Following the completion of the sale, the chief financial officer now owns 118,863 shares in the company, valued at approximately $7,573,950.36. This represents a 0.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO William Lewis sold 18,750 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $77.03, for a total value of $1,444,312.50. Following the sale, the chief executive officer now owns 334,186 shares of the company's stock, valued at approximately $25,742,347.58. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 514,731 shares of company stock worth $40,530,912 over the last quarter. 4.60% of the stock is currently owned by insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.